1. 2862 The influence of time to objective response on lenvatinib clinical outcomes in the phase 3 SELECT trial. (September 2015) Authors: Newbold, K.; Sherman, S.; Wirth, L.J.; Habra, M.A.; Rietschel, P.; Song, J.; Schlumberger, M.; Gianoukakis, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S577 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum. (1st November 2019) Authors: Ameri, A.H.; Mooradian, M.J.; Emerick, K.S.; Park, J.C.; Wirth, L.J.; Asgari, M.M.; Tsao, H.; Lawrence, D.; Sullivan, R.J.; Demehri, S. Journal: British journal of dermatology Issue: Volume 181:Number 5(2019) Page Start: 1095 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum. (7th August 2019) Authors: Ameri, A.H.; Mooradian, M.J.; Emerick, K.S.; Park, J.C.; Wirth, L.J.; Asgari, M.M.; Tsao, H.; Lawrence, D.; Sullivan, R.J.; Demehri, S. Journal: British journal of dermatology Issue: Volume 181:Number 5(2019) Page Start: 1095 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗